Go to deals
Healthcare

LDI has sold UltiMed to Levine Leichtman Capital Partners

UltiMed, Inc., a portfolio company of LDI, Ltd., has been sold to an investment vehicle sub-managed by Levine Leichtman Capital Partners, LLC.

UltiMed’s insulin pen needles, syringes and complementary products are critical offerings for diabetes patients who need daily insulin injections and for companion animals who increasingly suffer from this life-threatening disease. UltiMed’s proprietary “dispense and dispose” solutions provide diabetes patients a safe and convenient way to store used sharps following injection.

Levine Leichtman Capital Partners is a private equity and venture capital firm specializing in acquisitions, buyouts, recapitalizations, refinancing, balance sheet restructuring, growth financing, structured equity, distressed debt, leveraged loan and mezzanine investments in the middle market.

LDI, Ltd. is a private equity firm specializing in investing in acquisitions and add-on acquisitions. It is a family office based in Indianapolis, IN, with more than a century of experience funding and operating high-potential, middle-market companies.

One of Oaklins’ teams in the USA served as the exclusive financial advisor to UltiMed, Inc., a portfolio company of LDI, Ltd., in this transaction.

Service
M&A sell-side
Parties
“We selected the team based on their prior experience with UltiMed and their expertise in transactions in the diabetes and animal health sectors. They did an outstanding job of presenting UltiMed’s many strengths and growth opportunities to the market, and their deep relationships with potential acquirors were key to our success. We particularly appreciate the senior team focus they brought to completing this transaction despite the emergence of the COVID-19 pandemic in the midst of this assignment.”

John Martin

VP Corporate Development, LDI, Ltd.

Talk to the deal team

 Michael S. Goldman

Michael S. Goldman

Managing Director

New York, United States
Oaklins TM Capital
 Steven J. Hunter

Steven J. Hunter

Managing Director

Atlanta, United States
Oaklins TM Capital
 James  McLaren

James McLaren

Managing Director

New York, United States
Oaklins TM Capital
 John  Dean

John Dean

Associate Director

Atlanta, United States
Oaklins TM Capital

Related deals

Dental Holding has been acquired by Advantage Partners
Healthcare

Dental Holding has been acquired by Advantage Partners

Noritsu Koki Co., Ltd. has sold Dental Holding Inc. to Advantage Partners Inc.

Learn more
GeneTech Inc. has been acquired by Eurofins
Healthcare

GeneTech Inc. has been acquired by Eurofins

Noritsu Koki Co., Ltd. has sold GeneTech Inc. to Eurofins Clinical Testing Holding Lux S.à r.l.

Learn more
MediCa group has been acquired by Repharm
Healthcare

MediCa group has been acquired by Repharm

CGP Management has sold MediCa group, the largest private provider of healthcare services in Lithuania, to Repharm.

Learn more